Association of Psychological Distress in Patients With Lung Cancer
NCT06218901
Summary
Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. Psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. The systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect. In summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.
Eligibility
Inclusion Criteria: * Histologically proven diagnosis of lung cancer * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Not willing to participate in this clinical trial
Conditions8
Interventions2
Related trials
- A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. — David Palma
- AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer — IRCCS San Raffaele
- Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC — Peking University First Hospital
- Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer — The Second Hospital of Shandong University
- BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases — Shandong Cancer Hospital and Institute
- CIETAI and Sequential Radiotherapy in Squamous Lung Cancer — Dong Wang
- Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC — First People's Hospital of Hangzhou
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06218901